Are These The Best Health Care Stocks To Buy Before August 2021?
The health care industry is once again in the spotlight now as the world faces an uptick in coronavirus infections. As a result, it would not surprise me to see investors eyeing the top health care stocks in the stock market today. This would especially be the case now as World Health Organization General Director Tedros Ghebreyesus provided a grim update Wednesday. In the briefing, Ghebreyesus highlights that the world is in the early stages of another wave of coronavirus infections and deaths. Namely, countries across the globe are now facing various variants of concern that are more infectious, deadly, and resistant.
With all of this in mind, investors could once again be turning towards the health care industry. If anything, there are plenty of viable entry points for investors to choose from now. For instance, we could look at health care stocks like Johnson & Johnson (NYSE: JNJ) and Pacific Biosciences (NASDAQ: PACB). On one hand, JNJ currently estimates that its single-shot vaccine will generate $2.5 billion in sales this year. As another crucial player in the fight against the pandemic, JNJ stock would be in focus. Meanwhile, the likes of Pacific Biosciences remain hard at work sequencing the coronavirus genome providing long-term insight to the industry.
Not to mention, conventional day-to-day health care providers like CVS Health (NYSE: CVS) would also play a crucial role amidst the current pandemic. Overall, some would argue that now could be a good time to add some of the top health care stocks to your watchlist today. Should you feel the same, here are five names to know in the stock market now.
Top Health Care Stocks To Buy [Or Sell] This Week
- Trxade Health Inc. (NASDAQ: MEDS)
- Neurometrix Inc. (NASDAQ: NURO)
- Teladoc Health Inc. (NYSE: TDOC)
- Pfizer Inc. (NYSE: PFE)
- Cassava Sciences Inc. (NASDAQ: SAVA)
Trxade Health Inc.
Trxade Health is a health stock that provides efficient integrated pharmaceutical and medical services to pharmacies and consumers. The company combines its web-based purchasing platform to facilitate supply chain transactions between independent pharmacies, drug distributors, and manufacturers. Its impressive e-commerce platform delivers buyer/seller pricing algorithms, availability, and data analytics features. MEDS stock currently trades at $5.61 as of 3:55 p.m. ET and has been up by over 20% in the last month.
Investors could be reacting to news that its digital health care business subsidiary, Bonum Health has signed a Telemedicine Service Distribution Deal with Southeastern Grocers Inc. Southeastern Grocers is the parent company of Winn-Dixie, Harveys Supermarket, and Fresco y Mas grocery stores across the U.S.
In detail, Bonum Health will provide affordable telemedicine services and prescription discount savings to the patients of all of Southeastern Grocers brands in retail stores and pharmacies. With this exciting piece of news, will you consider buying MEDS stock?
- 4 Artificial Intelligence Stocks To Watch Right Now
- Best Lithium Battery Stocks To Buy Now? 4 To Know
NeuroMetrix is a health care company that focuses on developing and commercializing non-invasive medical devices. Specifically, its medical devices are used to diagnose and treat pain and neurological disorders. This would include DPNCheck, a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. NURO stock currently trades at $25.15 as of 3:55 p.m. ET and has skyrocketed by over 650% in the last 5 trading days.
This is due to the company receiving FDA breakthrough device designation for its Quell medical device. Quell is a wearable neurostimulation device for the treatment of fibromyalgia. It is an advanced, non-invasive, nerve stimulation device that is covered by 18 U.S. utility patents. It is the only wearable neurostimulator that is enabled by a custom-designed microchip that provides precise and high-power nerve stimulation.
The FDA program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment. All things considered, will you buy NURO stock?
Teladoc is a health care company that provides telemedicine. As a world leader in whole-person virtual care, the company proprietary health signals and personalized interaction to drive better health outcomes across the full continuum of care.
The company leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and health care professionals. TDOC stock currently trades at $152.61 as of 3:52 p.m. ET.
Last week, the company announced that it will be collaborating with Microsoft (NASDAQ: MSFT) to create a unified practice experience for clinicians. Teladoc’s Solo platform for hospitals and health systems will be integrated into the Microsoft Teams environment to strengthen physician and patient access to best-in-class virtual health care. Given the excitement surrounding this piece of news, will you add TDOC stock into your portfolio?
Next on this list is Pfizer. The company develops and manufactures health care products that include innovative medicines and vaccines. Most notably, it was the first company to receive FDA emergency use authorization (EUA) for its coronavirus vaccine.
It continues to collaborate with health care providers and governments all around the world to support and expand reliable health care. PFE stock currently trades at $41.50 as of 3:53 p.m. ET.
On Wednesday, the company announced that it will be collaborating with The Biovac Institute to manufacture and distribute its vaccine for distribution within the African Union. Biovac will perform manufacturing and distribution activities within Pfizer’s global vaccine supply chain and manufacturing network, which now span three continents and include more than 20 manufacturing facilities. Given how Africa is lagging behind in vaccination rollout, this could be a huge market for Pfizer to tap into. Would you consider investing in PFE stock for these reasons?
[Read More] Best Communication Stocks To Watch Right Now
Cassava Sciences Inc.
Last but not least, we have clinical-stage biopharmaceutical company Cassava Sciences Inc. For the most part, the company primarily focuses on developing novel therapeutics in the field of neuroscience. This would include the neurodegenerative disease of Alzheimer’s. The likes of which, according to Cassava’s estimates, impact over 5 million Americans today. As it stands, SAVA stock is currently trading at $125.29 a share as of 3:53 p.m. ET.
On Wednesday, the company provided a slew of updates on its Alzheimer’s disease drug, simufilam. For starters, Cassava will be teaming up with Premier Research International (PRI) to conduct its Phase 3 clinical trials of simufilam. In particular, CEO Remi Barbier highlights PRI’s impressive track record of neuroscience-related clinical studies as a key reason for this partnership. Secondly, the company provided a general mid-year corporate update.
This includes news about the company’s open-label study of simufilam achieving its target enrollment of 150 subjects. Thirdly, Cassava also revealed that it will be presenting two new clinical datasets at the 2021 Alzheimer’s Association International Conference next week. Given that all of these announcements were made on the same day, SAVA stock seems to be making waves now. Could this make it worth investing in for you now?